Please assess the completion status of the following clinical trial:

Trial Title: BAX 326 Surgery Study in Hemophilia B Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant and/or legal representative has/have voluntarily provided signed informed consent.~* Participant has severe (FIX level \< 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory.~* Participant requires surgery~* Participant has previously been treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 150 exposure days~* Participant has no evidence of a history of FIX inhibitors~* Participant is immunocompetent as evidenced by a CD4 count ≥ 200 cells/mm3.~* Participant is human immunodeficiency (HIV) negative or is HIV+ with a viral load \< 200 particles/μL \~ \< 400,000 copies/mL.~Main Exclusion Criteria:~* Participant has a history of FIX inhibitors with a titer ≥ 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening.~* Participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 Bethesda Units (BU) as determined by the Nijmegen modification of the Bethesda assay in the central laboratory.~* Participant has a history of allergic reaction or evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).~* Known hypersensitivity to hamster proteins or recombinant furin.~* Evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).~* Abnormal renal function~* Severe chronic liver disease~* Active hepatic disease with ALT or AST levels \> 5 times the upper limit of normal.~* Diagnosis of an iherited or acquired hemostatic defect other than hemophilia B.~* Platelet count \< 100,000/mL.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAX326 in Surgery (Type: EXPERIMENTAL): BAX 326 (recombinant factor IX) in Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).